32
Participants
Start Date
December 16, 2016
Primary Completion Date
July 3, 2024
Study Completion Date
July 3, 2024
Ixazomib
Ixazomib Capsules
UZ Leuven, Leuven
Asan Medical Center - PPDS, Seoul
University of Athens Medical School - Regional General Hospital Alexandra, Athens
Hospital Universitario de Donostia, Donostia / San Sebastian
Skanes Universitetssjukhus Lund, Lund
Emory University, Atlanta
Complejo Asistencial Universitario de Salamanca H. Clinico, Salamanca
Appalachian Regional Healthcare, Hazard
Washington University School of Medicine, St Louis
Peking University Third Hospital, Beijing
Peking Union Medical College Hospital, Beijing
National University Hospital, Singapore
Shanghai Chang Zheng Hospital, Shanghai
1st Affiliated Hospital of Zhejiang University, Hangzhou
Dana Farber Cancer Institute, Boston
Princess Margaret Cancer Centre, Toronto
University Health Network, Toronto
Laiko General Hospital of Athens, Athens
Tokyo Metropolitan Komagome Hospital, Bunkyo-Ku
Japanese Red Cross Medical Center, Shibuya-Ku
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzów
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz
Centrum Onkologii Ziemi Lubelskiej, Lublin
MTZ Clinical Research Sp z o o, Warsaw
Karolinska Universitetssjukhuset Huddinge, Stockholm
Karolinska Universitetssjukhuset Solna, Stockholm
Lead Sponsor
Takeda Development Center Americas, Inc.
INDUSTRY
Takeda
INDUSTRY